U.S. Markets open in 4 hrs 26 mins

Teva Pharmaceutical Industries Limited (TEVA)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
32.16-0.79 (-2.40%)
At close: 4:01PM EDT

32.40 0.24 (0.75%)
Pre-Market: 4:03AM EDT

People also watch
MYLGILDNVSAMGNABT
Full screen
Previous Close32.95
Open33.09
Bid32.10 x 1000
Ask32.22 x 200
Day's Range32.10 - 33.09
52 Week Range27.60 - 56.44
Volume4,140
Avg. Volume7,591,081
Market Cap32.67B
Beta0.52
PE Ratio (TTM)412.31
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.36 (4.13%)
Ex-Dividend Date2017-06-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • CNBC4 hours ago

    World's largest generic drugmaker warns health-care industry faces 'huge disruption'

    Yitzhak Peterburg, interim president and CEO of Teva Pharmaceutical, talks about the disruption facing the traditional health care industry.

  • This Biotech Crashed 28% Despite Positive Migraine Drug Tests
    Investor's Business Daily13 hours ago

    This Biotech Crashed 28% Despite Positive Migraine Drug Tests

    Alder stock dove to a nearly three-year low Tuesday despite strong data in a Phase 3 migraine trial, making it competitive with Lilly, Amgen and Teva.

  • Barrons.com15 hours ago

    Valeant: Out of the Frying Pan, Into the Fire

    Shares of Valeant Pharmaceuticals International (VRX) spiked yesterday on speculation regarding a possible debt-to-equity swap by the troubled drug maker. Wells Fargo analyst David Maris weighed in on the notion today, arguing that even if a swap does happen, it does not repair poor business trends or the increasingly unlikelihood that Valeant can deliver the strong earnings growth promised by consensus forecasts. As Maris writes: Based on our experience and feedback from our high yield debt analyst, we think that most debt holders do not have the ability or interest to take cross structure risk.